Clinical Trial Update: Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease [Phase 1, Phase 2]

View source ↗

Summary

Infliximab was studied in a Phase 1/2 trial for Crohn's-like inflammatory bowel disease in patients with chronic granulomatous disease. The study was terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Granulomatous Disease

Drugs mentioned

• Remicade (infliximab)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Chronic Granulomatous Disease, Crohn'S-like IBD | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2015-12-29